Merck and Moderna report Phase 3 melanoma trial results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Merck & Co. (NYSE: MRK) | Delayed: 145.27 -1.97 (1.34%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $147.24 | 52 Week High | $65.46 | |||
| Open | $145.02 | 52 Week Low | $47.97 | |||
| Day High | $145.44 | P/E | 98.82 | |||
| Day Low | $143.41 | EPS | $1.47 | |||
| Volume | 8,381,045 | |||||
| Marina Biotech, Inc. (NASDAQ: MRNA) | Delayed: 200.10 -2.53 (1.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $202.63 | 52 Week High | $0.52 | |||
| Open | $196.69 | 52 Week Low | $0.08 | |||
| Day High | $206.97 | P/E | N/A | |||
| Day Low | $183.00 | EPS | $-3.80 | |||
| Volume | 21,554,941 | |||||
